Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ARGX |
---|---|---|
09:32 ET | 901 | 397.11 |
09:34 ET | 500 | 394.635 |
09:36 ET | 680 | 395.93 |
09:38 ET | 200 | 395.655 |
09:39 ET | 300 | 395.14 |
09:41 ET | 300 | 395.91 |
09:43 ET | 400 | 395.71 |
09:45 ET | 300 | 395.465 |
09:48 ET | 100 | 395.4 |
09:52 ET | 100 | 395.695 |
09:54 ET | 100 | 395.9 |
09:56 ET | 200 | 395.74 |
09:59 ET | 300 | 394.96 |
10:01 ET | 200 | 394.04 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
argenx SE | 23.6B | -76.6x | --- |
Alnylam Pharmaceuticals Inc | 19.4B | -42.5x | --- |
Sarepta Therapeutics Inc | 12.2B | -21.0x | --- |
Bio-Techne Corp | 10.9B | 50.5x | +23.61% |
Neurocrine Biosciences Inc | 13.7B | 56.5x | +62.04% |
Biomarin Pharmaceutical Inc | 16.7B | 100.5x | --- |
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.6B |
---|---|
Revenue (TTM) | $1.2B |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.65 |
EPS | $-5.14 |
Book Value | $69.22 |
P/E Ratio | -76.6x |
Price/Sales (TTM) | 19.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.66% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.